About US
Contact us
-
K-V says it will go bankrupt without FDA interventionK-V Pharmaceutical ($KV.A) claims in a lawsuit that if the FDA does not allow it to exclusively make the premature birth drug Makena and charge 35 times more per injection than compounders, its busine2012/7/9
-
Genentech's R&D takes the prize at RocheWhen Roche ($RHHBY) bought out Genentech back in 2009, analysts fretted over the looming culture clash as the corporate types of Basel invaded San Francisco. But the real showdown was taking place bet2012/7/4
-
U.K. to spend less on branded drugs, report findsDrugmakers can't get a break in Europe these days. Bad debt in Greece and Spain. Price cuts not only in troubled southern Europe, but Germany and France, too. And now, a report shows that U.K. spendin2012/7/4
-
New week, new winner in the top pharma settlements contestLast week, when we unveiled our Top 10 Pharma Settlements report, we promised to update it as new deals hit the news. We didn't realize we'd need to fulfill that promise so quickly. Today, GlaxoSmithK2012/7/3
-
GlaxoSmithKline, Theravance tout new data on COPD drugsIn the race for new COPD drugs, GlaxoSmithKline ($GSK) and Theravance ($THRX) have released new data from a slew of late-stage studies of their LAMA/LABA combo for COPD. The key finding is that their2012/7/3
-
Pharma gets what it bargained for in Supreme Court rulingAlong with the Supreme Court's decision that, for the most part, the Affordable Healthcare Act is constitutional has come a firestorm of analysis of what it means to drug companies going forward: more2012/7/2
-
India to begin paying for drugs for 'everyone'It looks like the pharma industry may have gotten through to the government in India about the need to expand public access to healthcare. Currently,Indian patients needing healthcare, including drugs2012/7/2
-
• GSK chief: Europe's woes may slice pharma prices by 6%European price cuts are taking an even bigger bite out of GlaxoSmithKline's ($GSK) sales than CEO Andrew Witty had expected--and he expected a sizable one.2012/6/28
-
NICE says yes to Tarceva, Zytiga, Botox, no to Herceptin, TyverbIt was three yeas and two nays from the National Institutes of Health and Clinical Excellence today. Allergan ($AGN) got approval for a new use for Botox, Johnson & Johnson's ($JNJ) Janssen unit2012/6/28
-
Roche slashes 1,000 jobs in closure of Nutley R&D siteIn a major restructuring of its global R&D operations, Roche has just announced that it is closing its sprawling center in Nutley, NJ, axing 1,000 staffers and redistributing research activities i2012/6/27